Human Herpesvirus 6 Infection after Autologous or Allogeneic Stem Cell Transplantation: A Single‐Center Prospective Longitudinal Study of 92 Patients

Imbert-Marcille, Berthe-Marie; Tang, Xiangliang; Lepelletier, Didier; Besse, Bernard; Moreau, Philippe; Billaudel, S.; Milpied, Noël

doi:10.1086/318142

Cited by 105 publications

(78 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delayed platelet engraftment associated with HHV6 reactivation have been described in several studies, 4,13,15,[17][18][19][20] but this was not confirmed by others. [21][22][23] This is possibly caused by the low number of patients and variation in the conditioning regimens.…”

Section: Incidence Of Hhv6 Reactivation and Clinical Manifestations Amentioning

confidence: 87%

Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation

Pagter

Schuurman

Meijer

et al. 2008

Journal of Clinical Virology

View full text Add to dashboard Cite

a b s t r a c tHuman herpesvirus type 6 (HHV6) is known to reactivate after hematopoetic stem cell transplantation (HSCT) and has been suggested to be associated with increased mortality and severe clinical manifestations, including graft versus host disease (GvHD). The exact etiological role of HHV6 reactivation in increased morbidity and mortality after HSCT remains unclear. This review will focus on the current available evidence of HHV6 reactivation after HSCT and its immuno-modulatory capacities, with particular emphasis on the severe complication GvHD. At present, no effective specific antiviral treatment for HHV6 reactivation has been identified. The currently available antiviral agents are outlined, as well as possible future strategies for the treatment of HHV6 reactivation. Non-toxic, specific treatment or prevention of HHV6 reactivation might improve the safety and efficacy of the HSCT procedure.

show abstract

Section: Incidence Of Hhv6 Reactivation and Clinical Manifestations Amentioning

confidence: 87%

Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation

Pagter

Schuurman

Meijer

et al. 2008

Journal of Clinical Virology

View full text Add to dashboard Cite

show abstract

“…In our study, along with others, we have already reported the main consequence of HHV6 infection was to delay neutrophil and plt recoveries, especially in early reactivating patients. 25,27,37 Delayed engraftment is a well-known complication of cord blood transplant occurring at a higher incidence when compared with other source of SCs. [1][2][3][4]6 The role of HHV6 in delayed engraftment raises logically the question of HHV6 prophylaxis in CB transplant.…”

Section: Discussionmentioning

confidence: 99%

Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source

Chevallier

Hebia-Fellah²,

Planche

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Occurrence of CMV, EBV and human herpes virus 6 (HHV6) infections and immune reconstitution were compared in 15 adult patients receiving a cord blood transplantation (CBT) and 40 patients who received an allogeneic transplantation from a matched unrelated donor (MUD). Herpes virus DNA quantifications in the blood (459 samples) were performed before and then monthly up to 9 months after transplant and the main lymphocytes populations were counted at 3, 6 and 9 months. Incidence of HHV6 infection was significantly higher in the CBT group (80 vs 42.5%; Po0.0001), with higher viral load (Po0.0001). In multivariate analysis, the use of a CBT and a myeloablative conditioning regimen were found to increase the risk of HHV6 infection (odds ratio (OR) ¼ 5.4, P ¼ 0.02 and OR ¼ 3.5, P ¼ 0.04, respectively). Incidences of CMV were similar between the two groups whereas MUD increased the risk of EBV infection, in univariate analysis only. HHV6 reactivation translated toward delayed neutrophils and plts engraftment in the two groups. MUD and CBT do not share the same immune reconstitution patterns, notably for B and CD8 lymphocytes and NK cells. There is a strong and specific relationship between HHV6 infection and the use of cord blood cells.

show abstract

“…HHV-6 infection appears to be common following allogeneic marrow transplantation. 6,7 The immature immune capability and the lower stem cell dose of umbilical cord blood may further increase the risk of viral infection. Two of our subjects required additional steroid therapy for acute GVHD before diagnosis of encephalitis.…”

Section: Discussionmentioning

confidence: 99%

Human herpesvirus-6 encephalitis after unrelated umbilical cord blood transplant in children

Chik

Chan

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Three children developed human herpesvirus-6 (HHV-6), variant B encephalitis after unrelated umbilical cord blood transplant, in a single center. They developed clinical manifestations of encephalitis around day 17 post transplant. Impairment of consciousness, incoherent speech, episodic focal pruritis, motor weakness, convulsions and severe hyponatremia were features at presentation. Radiological investigation of brain ranged from unremarkable to extensive white matter and meningeal lesions. Diagnosis was established by the presence of HHV-6 DNA in cerebrospinal fluid (CSF). Retrospective analyses of plasma revealed the presence of viral DNAemia prior to the onset of disease in two subjects. Treatment with ganciclovir or foscarnet was given. Two subjects did not achieve engraftment and died of other transplant-related complications on day 38 and 56 posttransplant, respectively. One subject achieved diseasefree survival for more than 1 year with a satisfactory neurological outcome. In conclusion, HHV-6 encephalitis is not uncommon among patients undergoing umbilical cord blood transplantation. It is worth conducting further studies on early diagnosis and optimal management of this potentially fatal disease. Bone Marrow Transplantation (2002) 29, 991-994.

show abstract

Human Herpesvirus 6 Infection after Autologous or Allogeneic Stem Cell Transplantation: A Single‐Center Prospective Longitudinal Study of 92 Patients

Cited by 105 publications

References 31 publications

Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation

Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation

Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source

Human herpesvirus-6 encephalitis after unrelated umbilical cord blood transplant in children

Contact Info

Product

Resources

About